Journey Medical Stock Crashes 30% After Reimbursement Disclosure Sparks Fraud Investigation
Pomerantz LLP investigates $DERM for potential securities fraud after revealing prescription-revenue disconnect tied to reimbursement timing issues.
DERMsecurities fraudclass action lawsuit